Trial ID or NCT#

NCT01868451

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to compare the outcomes across the 4 different treatment groups. The investigators hope that this treatment will improve the ability to cure more patients with HL and also limit the long-term side effects from the treatment. Although eliminating radiation in cohort 4 will eliminate the risk for long-term side effects from radiation, it is also possible that with BV+AVD chemotherapy alone there may be an increased risk of the Hodgkin lymphoma coming back after initial treatment.

Official Title

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Lauren Maeda
Lauren Maeda
Medical oncologist, Hematologist, Lymphoma specialist
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Ranjana Advani
Ranjana Advani
Medical oncologist, Lymphoma specialist
Saul A. Rosenberg, MD, Professor of Lymphoma
Neel K. Gupta
Neel K. Gupta
Medical oncologist
Clinical Assistant Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

Sipra Choudhury
(650) 736-2563